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Selecting differentially expressed genes (DEGs) is one of the most important tasks in microarray applications for studying 
multi-factor diseases including cancers. However, the small samples typically used in current microarray studies may only par-
tially reflect the widely altered gene expressions in complex diseases, which would introduce low reproducibility of gene lists 
selected by statistical methods. Here, by analyzing seven cancer datasets, we showed that, in each cancer, a wide range of 
functional modules have altered gene expressions and thus have high disease classification abilities. The results also showed 
that seven modules are shared across diverse cancers, suggesting hints about the common mechanisms of cancers. Therefore, 
instead of relying on a few individual genes whose selection is hardly reproducible in current microarray experiments, we may 
use functional modules as functional signatures to study core mechanisms of cancers and build robust diagnostic classifiers.  
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With data from microarrays, one of the most important tasks 
is to identify differentially expressed genes (DEGs) which 
would be “significant” or “important” enough for the fol-
low-up studies [1–3]. However, DEG lists produced from 
different studies for a cancer are usually highly inconsistent 
[4,5]. As recently demonstrated by us [6], even when tech-
nical measurement variations are small, DEG lists correctly 
determined by a statistical method such as SAM (Signifi-
cance Analysis of Microarrays) [1] from different microar-
ray studies for a cancer still tend to be highly inconsistent. 
Under such situations, selecting DEGs solely based on sta-
tistical cut-off criteria (e.g., a false discovery rate (FDR) 
level) becomes less relevant [7–9]. However, functional 
modules significantly enriched with DEGs tend to be robust 
to the uncertainty introduced by DEG selection [10,11], as 
also formally demonstrated by us recently [12]. 
In this work, we used another approach to identify func-
tional modules with high disease discrimination abilities for 
cancers. Our results demonstrated that many functional 
modules have high disease discrimination abilities for the 
five types of cancers originating in different tissues, indi-
cating that each cancer involves the disruption of various 
cellular processes and genes in these functions undergo 
broad expression changes [13,14]. Especially, the modules 
shared by the five types of cancers also cover a wide range 
of functions, suggesting the mechanisms shared by various 
cancers. Obviously, understanding the mechanisms shared 
by various cancers has important diagnostic implications. 
For example, the selected modules can be used as functional 
signatures to build robust cancer diagnostic classifiers [15]. 
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1  Materials and methods 
1.1  Datasets  
The data analyzed in this study was downloaded from Gene 
Expression Omnibus database (GEO) [16], as summarized 
in Table 1.  
Table 1  Seven cancer datasets used in this study  




Lung cancer [17] 18 (13 versus 5) 9476 
Lung cancer [18] 38 (21 versus 17) 8751 
Colorectal cancer [19] 23 (15 versus 8) 19772 
Colorectal cancer [20] 64 (32 versus 32) 19772 
Prostate cancer [21] 103 (62 versus 41) 12953 
Gastric cancer [22] 132 (103 versus 29) 14123 
Liver cancer [23] 156 (82 versus 74) 9350 
 
The cDNA data was log2-transformed and then normal-
ized to be with median 0 and standard deviation 1 per array, 
as adopted in Oncomine database [24]. The CloneIDs with 
missing rates above 20% were deleted, and the other miss-
ing values were replaced by using the k-Nearest Neighbor 
(KNN) imputation algorithm (k=15) [17]. The Affymetrix 
GeneChip data was preprocessed by RMA (Robust Multi-      
array Analysis). The most recent (July 2008) SOURCE da-
tabase [25] was used for annotating CloneID to GeneID. 
1.2  Evaluating functional expression changes of can-
cers by KNN classifiers 
Based on each “Biological Process” term of Gene Ontology 
(GO) [26] (downloaded in October 2008), we built a KNN 
classifier [27] to classify samples in a dataset, where the 
Euclidean distance between two samples was calculated 
based on, in these samples, the expression values of the 
genes annotated to the GO term. Then, for each sample, we 
found its k (=3) nearest samples and classified this sample 
with the majority vote of the labels of its k nearest 
neighbors. The performance of a KNN classifier was evalu-
ated by a leave-one-out cross-validation (LOOCV) proce-
dure, in which each sample was left out in turn to calculate 
the accuracy rate (the percentage of the correct predictions) 
[28]. When a classifier achieved an accuracy rate above a 
threshold (e.g., 90%), we referred to the corresponding GO 
term as a functional module, indicating that the genes de-
scribed by it can characterize the disease.  
GO terms are hierarchically organized and thus are 
highly redundant. Some algorithms were designed to reduce 
this redundancy, for example, by eliminating genes mapped 
to significant GO terms from more general GO terms [29] 
or by weighting genes based on the scores of neighboring 
GO terms [30]. However, all these methods rely on specific 
assumptions which need to be further evaluated. Here, for 
the purpose of this study, we applied a simple method: 
Eliminating a functional module if one of its offspring terms 
can also achieve the given accuracy rate level. The specific 
terms identified by this method are sufficient to support our 
conclusion that biological pathways are widely disturbed in 
cancers. 
1.3  Up/down-regulated genes enrichment in the mod-
ules 
To test whether the shared modules were significantly up- 
(or down-) regulated in a cancer, we first found the up- (or 
down-) regulated genes in each module. In a cancer dataset, 
a gene was defined as up- (or down-) regulated if its mean 
expression value in the cancer samples is greater (or less) 
than that in the normal samples. Then, we calculated the 
fraction of up- (or down-) regulated genes in each module 
and used the hypergeometric distribution model to calculate 
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where x is the number of the up- (or down-) regulated genes 
in the module and N is the number of all the measured genes 
in the module. K is the number of up- (or down-) regulated 
genes and M is the total number of genes in the dataset. 
2  Results 
2.1  Functional modules with high disease discriminat-
ing abilities 
Using KNN classifiers, for prostate, liver, lung, gastric and 
colorectal cancers respectively, we found 26, 60, 135, 182 
and 334 functional modules with classification accuracy 
rates exceeding 90%. This result demonstrated that func-
tional modules with high disease discriminating abilities 
cover a wide range of functions globally perturbed in can-
cer. 
Importantly, setting the threshold of disease classification 
accuracy above 85%, we found seven modules shared by all 
the seven datasets for five types of cancers (Table 2), sug-
gesting hints about common mechanisms of these cancer 
types.  
2.2  Seven functional modules shared by different can-
cer types  
Hanahan and Weinberg [31] suggested that six functional 
hallmarks are shared in common by perhaps all types of  
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Table 2  Seven functional modules with classification accuracy >85% for all the seven datasetsa) 
GO term Prostate Liver Gastric Lung [17] Lung [18] Colorectal [19] Colorectal [20] 















































































































a) The subscript u or d represents P-values for up-regulated or down-regulated genes in the modules. 
 
 
human cancers. Indeed, the functional modules found here 
are significantly associated with these hallmarks.  
(i) The module “positive regulation of I-kappaB kinase/      
NF-kappaB cascade” is often regarded as pro-oncogenic 
signal which is a part of growth signals (the first hallmark). 
Inhibitors of the NF-kappaB pathway were recently used 
with success as treatment against cancer [32]. In this mod-
ule, NF-kappaB p65, an oncogene activated in gastric car-
cinoma tissue [33], was measured in six datasets except the 
dataset for prostate cancer. We found it was up-regulated in 
five datasets but down-regulated in liver cancer (Table 2). 
(ii) The module “transcription initiation from RNA po-
lymerase II promoter” plays an important role in cancer cell 
proliferation. In this module, alternation of the function of 
E2F transcription factors will render cells insensitive to 
antigrowth factors, which is the second acquired capability 
of cancer cells. We found that in this module, transcription 
factors such as E2F2, E2F3 and many other transcription 
initiation factors were significantly up-regulated in tumor 
samples in all the seven datasets (Table 2). 
(iii) The module “cell cycle arrest” is a process by which 
the cell cycle is halted during one of the normal phases. For 
example, cells in G1 phase suffering DNA damage do not 
enter S phase [34]. This alternation can make cancer cells to 
evade apoptosis, the third hallmark of cancer. In this mod-
ule, p53 (Tp53) was up-regulated in six of the seven data-
sets except in prostate cancer. 
(iv) The module “water transport” is also associated with 
cancer. The mechanism of cell migration, which is an initial 
step in angiogenesis (the fifth hallmark), can be determined 
by the osmotically driven water properties of the channel 
[35]. Saadoun et al. [36] showed that deletion of water 
channel aquaporin-1 (AQP-1) may reduce endothelial cell 
migration. We found the AQP-1 gene was down-regulated 
in all the seven datasets and the “water transport” module 
was significantly down-regulated in five of the seven data-
sets except the two colorectal cancer datasets (Table 2).  
(v) Another three functional modules, “epithelial to 
mesenchymal transition”, “regulation of bone mineraliza-
tion” and “homophilic cell adhesion”, are involved in the 
“tissue invasion and metastasis” capability (the sixth cancer 
hallmark). During epithelial-mesenchymal transition (EMT), 
epithelial cells become independent of their neighbors and 
can move freely. In this way, tumors derived from epithelial 
cells become motile and may invade lymph or blood vessels 
[37], accompanied by cell-cell adhesion. The module “ho-
mophilic cell adhesion” involves the tethering of cells to 
their surroundings in a tissue. It is known that E-cadherin, a 
cell-cell adhesion receptor, is an important determinant of 
tumor progression, serving as a suppressor of invasion and 
metastasis in many cancers [38]. We found the E-cadherin 
was up-regulated in prostate and lung cancer datasets, but 
down-regulated in liver, gastric and colorectal cancer data-
sets. “Bone mineralization” module is important in cancer 
metastasis [39]. In this module, bone morphogenetic protein 
2 (BMP2) genes were down-regulated in all the seven data-
sets, which may induce medulloblastoma cell apoptosis 
[40].  
Notably, the result that the seven modules are involved in 
five of the six cancer hallmarks suggests that these modules 
are common in tumorigenesis. The fourth hallmark (limit-
less replicative potential) characterized with telomere 
maintenance was not found by our approach largely because 
it was only annotated with about 20 genes. However, we 
found the classification accuracy of this module was beyond 
90% for lung, colorectal and gastric cancer. 
3  Discussion 
By analyzing seven datasets for the five cancer types, we 
found that a wide range of functional modules were altered 
globally in cancers and thus had high disease classification 
abilities. Notably, for evaluating the disease relevance of the 
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functional expression of genes in a GO term, we built a 
classifier by using all the genes annotated to a GO term in-
stead of selecting a few DEGs. Classifiers built in such a 
way are not affected by the uncertainty of DEGs selection, 
though they might not be able to achieve the best perform-
ance in a dataset. Actually, the classification accuracy and 
robustness could be improved by comparing algorithms 
based on different hypotheses. Especially, by integrating 
gene expression profiles with other data sources, we may 
also improve the diagnosis of many cancers. For example, 
by integrating gene expression profiles with protein interac-
tions, Chuang [41] identified protein interaction subnet-
works with coherent expression patterns of their component 
genes, which were efficient in classifying cancer metastasis. 
Similarly, Taylor [42] showed that the change of global 
modularity of human interactome can be used to assess 
cancer outcome. Improving algorithms by integrating di-
verse data sources to increase the classification accuracy 
and robustness for cancers deserves our future work. 
Our results also suggest that alterations in some biologi-
cal pathways may be specific to a cancer. For example, 
“vesicle” associated modules can achieve a higher classifi-
cation accuracy rate for prostate caner whereas “viral ge-
nome replication” and “virion transport” modules can achieve 
a higher classification accuracy rate for liver cancer. How-
ever, whether this difference of modules in classification 
accuracy rate for different cancers could suggest some can-
cer specificity modules needs to be further studied. In our 
recent study [12,43], we found gene expressions are widely 
changed and highly consistent in different cancers when 
considering correlated gene expressions, suggesting that the 
expression patterns of the altered genes in different cancers 
tend to be similar. Because of the correlation structure of 
gene expressions, it would be hard to identify cancer spe-
cific expression changes in current small-scaled microarray 
experiments. Therefore, in this study, we only highlighted 
functional modules shared by various cancers.  
Finally, we note that the identified modules such as cell 
cycle, signaling and growth regulatory modules are similar 
with the modules identified by Segal et al. using gene en-
richment analysis [44]. However, our findings do not rely on 
individual genes whose selection is hardly reproducible. 
These modules can serve as functional signatures for build-
ing robust cancer classifiers. On the other hand, the tradi-
tional task of extracting biologically important individual 
genes still warrants investigations. For example, in our fu-
ture work, we may focus on studying functional modules 
enriched with highly altered genes in cancer [45] to find in-
dividual genes which may play key roles in tumorigenesis. 
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